Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

NEXT STORY
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management
PREV STORY
Tissue Sealants and Adhesives (Wound Care Management) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TeleTracking releases enterprise COVID-19 capacity and census dashboard to bring visibility to health systems

author_avatar
NASDAQ Market News

NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy

PHILADELPHIA and OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ...

author_avatar
NASDAQ Market News

Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage ...

author_avatar
NASDAQ Market News